Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2005 2
2008 1
2009 1
2011 3
2012 3
2013 3
2014 3
2015 1
2016 1
2017 1
2018 1
2019 1
2020 1
2021 3
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study.
Deneuve S, Bastogne T, Duclos M, Mirjolet C, Bois P, Bachmann P, Nokovitch L, Roux PE, Girodet D, Poupart M, Zrounba P, Claude L, Ferella L, Iacovelli NA, Foray N, Rancati T, Pereira S. Deneuve S, et al. Among authors: poupart m. Tumori. 2023 Apr;109(2):173-185. doi: 10.1177/03008916221078061. Epub 2022 May 16. Tumori. 2023. PMID: 35578746
Proof of Concept of a Binary Blood Assay for Predicting Radiosensitivity.
Deneuve S, Mirjolet C, Bastogne T, Duclos M, Retif P, Zrounba P, Roux PE, Poupart M, Vogin G, Foray N, Pereira S. Deneuve S, et al. Among authors: poupart m. Cancers (Basel). 2021 May 19;13(10):2477. doi: 10.3390/cancers13102477. Cancers (Basel). 2021. PMID: 34069662 Free PMC article.
Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule.
Pêtre A, Dalban C, Karabajakian A, Neidhardt EM, Roux PE, Poupart M, Deneuve S, Zrounba P, Fayette J. Pêtre A, et al. Among authors: poupart m. Oncotarget. 2018 Apr 24;9(31):22038-22046. doi: 10.18632/oncotarget.25157. eCollection 2018 Apr 24. Oncotarget. 2018. PMID: 29774120 Free PMC article.
Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.
Fayette J, Fontaine-Delaruelle C, Ambrun A, Daveau C, Poupart M, Ramade A, Zrounba P, Neidhardt EM, Péron J, Diallo A, Céruse P. Fayette J, et al. Among authors: poupart m. Oncotarget. 2016 Jun 14;7(24):37297-37304. doi: 10.18632/oncotarget.8934. Oncotarget. 2016. PMID: 27119503 Free PMC article.
Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J, Molin Y, Lavergne E, Montbarbon X, Racadot S, Poupart M, Ramade A, Zrounba P, Ceruse P, Pommier P. Fayette J, et al. Among authors: poupart m. Drug Des Devel Ther. 2015 Nov 26;9:6203-10. doi: 10.2147/DDDT.S81488. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26648696 Free PMC article.
28 results